Pfizer Inc

Summary (from latest quarterly report – 2015)

• Total equity  : 66.83 billion USD
• Market Cap is 185.3 billion USD ( last price of the stock is 30.02 USD)
• Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health, and Consumer Healthcare
• Equity of total company decreased from 71.3 billion USD in 2014 to 66.83 billion in 2015
• Company has 3 billion USD in cash on account
• Total equity – cash on account = 66.83 billion usd - 3 billion usd = 63.83 billion usd
• In 2015 company has 29.07 billion usd long-term debt, short – term debt was 9.8 billion usd

In 2014 company had 31.54 billion usd long-term debt, short-term debt was 5.14 billion usd

• Pfizer balance sheet has become weaker in 2015 (In latest quarterly report - total equity decreased to 66.83 billion USD from 71.3 in 2014, total debt was 38.87 billion usd in 2015)
• Company's revenue decreased in latest annual report  to 49.6 billion usd from 51.58 billion in 2013
• Net income decreased in latest annual report  to 9.13 billion usd from 22 billion in 2013
•  In 2014 company paid 6.6 billion usd dividend to its shareholders

Pfizer Inc Subsidiaries

Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health, and Consumer Healthcare. Pfizer has made numerous acquisitions, including Warner–Lambert in 2000, Pharmacia in 2003, and Wyeth in 2009.

• Pfizer acquired Warner–Lambert in 2000 for 110 billion usd (Pfizer paid 90.3 billion usd in stock and rest in cash to acquire Warner-Lambert)
• Pfizer merged with  Pharmacia in 2003 for 60 billion usd in stock (Pharmacia shareholders receive 1.4 shares of Pfizer stock for each share of Pharmacia)
• Pfizer acquired in 2007 Coley Pharmaceutical for 164 million usd
• Pfizer acquired in 2008 CovX for an undisclosed sum
• Pfizer acquired in 2008 Encysive Pharmaceuticals  for 195 million usd
• Pfizer acquired Wyeth  in 2009 for 68 billion usd
• In October 2010, Pfizer agreed to buy King Pharmaceuticals for 3.6 billion usd
• Pfizer acquired in 2011 Icagen  for 60 million usd
• Pfizer acquired in 2011 Excaliard Pharmaceuticals for 14 million usd
• Pfizer acquired in 2012 Alacer for 360 million usd
• Pfizer acquired in 2012 NextWave Pharmaceuticals  for 700 million usd
• In 2014 Pfizer acquired Innopharma for 225 million usd, plus up to 135 million usd in milestone payments
• Pfizer acquired Redvax  in 2015 for an undisclosed sum
• In February 2015, Pfizer and Hospira agreed that Pfizer would acquire Hospira for 15.2 billion usd in cash

Total = 258.65 billion usd

On November 23, 2015, Pfizer and Allergan, Plc announced their intention to merge for an approximate sum of 160 billion usd, making it the largest pharmaceutical deal ever, and the third largest corporate merger in history. As part of the deal, the Pfizer CEO, Ian Read, will remain as CEO and chairman of the new company, to be called "Pfizer, plc", with Allergan's CEO, Brent Saunders, becoming president and chief operating officer. As part of the deal, Allergan shareholders will receive 11.3 shares of the company, with Pfizer shareholders receiving one. The terms propose that the merged company will maintain Allergan's Irish domicile, resulting in the new company being subject to corporation tax at the Irish rate of 12.5%

Opinion about the company

Fundamentally it is a good company and in the future we can expect its growth (Total debt is very big (38.87 billion usd), company has 3 billion USD in cash on account  , ROE is around 11 %).